bing the intimal surface with a cotton bud moistened with Krebs solution. Successful removal of endothelial cells was confirmed by the inability of acetylcholine (1 M) to induce relaxation. Using a pair of stainless steel hooks with a resting tension of 500 mg, the rings were mounted in organ baths containing 5 ml Krebs solution, which was maintained at 37˚C and bubbled with a 95% O 2 and 5% CO 2 mixture. One of the hooks was connected to a force transducer (Orientec, Tokyo, Japan), and the developed tension was displayed on a polygraph (model no. RJG4128; Nihon Kohden, Tokyo, Japan). The bath fluid was changed and the resting force was readjusted every 20 minutes until a stable baseline was attained (usually after ~60 minutes). Each preparation was challenged with 1 M noradrenaline to measure the contractile force of each preparation, and the ET-1-induced contractile responses were represented as percentages of the tension induced by 1 M NA. Unless specified otherwise, inhibitors were added 30 minutes before stimulation.
Experimental Protocols in the ET-1-Induced Vasospasm Model
Japanese white rabbits weighing 3 kg each were randomly assigned to six experimental groups of six animals each. Groups 1 and 2 consisted of animals that received cisternal injections of saline. The rabbits in Groups 3 and 4 received injections of 10 nM ET-1. Thirty minutes before cisternal administration of saline or ET-1, animals in Groups 2 and 4 received cisternal injections of AG1478. Follow-up angiography studies were performed 2 hours after cisternal injection of ET-1. Data from a previous report demonstrate that the degree of vasoconstriction by ET-1 persisted for more than 24 hours.
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Animals were anesthetized with sodium pentobarbital (35 mg/kg, administered intravenously) and allowed to breathe spontaneously. A catheter was introduced into the VA via the transfemoral approach. Vertebral artery angiography studies were performed with the aid of a bolus injection of 3 ml Iopamiron. After control angiography, the cisternal magna was punctured percutaneously by using a 21-gauge butterfly needle. Endothelin-1 (1 ml) and/or AG1478 (1 ml) were then injected. To avoid a marked increase in intracranial pressure, the same amount of cerebrospinal fluid was removed before the first injection. After the injection, the animals were housed flat in animal incubators. Vertebral artery angiography studies were performed again to obtain the magnitude of the BA contraction. The caliber of the BA was measured on x-ray films at three corresponding cross sections (at levels just below the BA-posterior cerebral artery junction, just above the BA-VA junction, and midway between these locations), and these three values were averaged as described previously. 10 
Sources of Supplies
All chemicals were obtained from the following sources: ET-1 from the Peptide Institute (Osaka, Japan); AG1478 from Funakoshi (Tokyo, Japan); and PD98059 from Wako (Osaka, Japan). All other chemicals were reagents and were commercially available.
Statistical Analysis
All results were expressed as the means Ϯ SEM. Data were subjected to a two-way analysis of variance, and when a significant F value was encountered, the Newman-Keuls multiple-range test was used to test for significant differences among treatment groups. A probability level of less than 0.05 was considered statistically significant.
Results

Effects of ET-1 on ERK1/2 Activity
After stimulation with 10 nM ET-1, ERK1/2 activity in the cytosolic fraction increased with time and at 5 minutes reached a peak of approximately four times greater than prestimulation values, as described previously. 9 Thus, stimulation time was set at 5 minutes.
Endothelin-1 stimulated ERK1/2 activity in a concentration-dependent manner, with an EC 50 value of approximately 1 nM; the maximal effect was observed at a concentration of at least 10 nM (Fig. 1A) . The ET-1-induced ERK1/2 activity was abolished by 5 M BQ123, a specific blocker of the ET-A receptor, but was unaffected by 5 M BQ788, a specific blocker of ET-B receptor (data not shown). The PD98059 (Fig. 1B) . Thus, 10 M PD98059 was used in the following experiments.
Effects of PD98059 on ET-1-Induced Contractions of Rabbit BA Rings Without Endothelium
To test the effects of ERK1/2 on ET-1-induced contractions, we used PD98059. Because ET-1 failed to induce remarkable contractions in BA rings with intact endothelium (data not shown), we used BA rings without endothelium. Endothelin-1 induced contractile responses in rabbit BA rings without endothelium in a concentration-dependent manner ( Fig. 2A) , as described previously. 8 More specifically, PD98059 inhibited ET-1-induced contractions (Fig.  2B ). Maximal inhibition of approximately 80% was obtained at concentrations of at least 10 M PD98059. These results indicate that ERK1/2 are involved in ET-1-induced contractions of rabbit BA rings.
Effects of AG1478 on ET-1-Induced EGFR-PTK Transactivation
Transactivation of EGFR PTK by 10 nM ET-1 increased with time and reached the peak value after approximately 2 minutes, as described previously. 7 Thus, the stimulation time was set at 2 minutes. Endothelin-1 activated EGFR PTK in a concentration-dependent manner, with EC 50 val- ues of approximately 1 nM (Fig. 3A) . Stimulation reached its maximum at concentrations of 10 nM or more. The AG1478, a specific inhibitor of EGFR PTK, inhibited ET-1-induced EGFR-PTK transactivation in a concentrationdependent manner, with IC 50 values of approximately 10 nM (Fig. 3B ). Up to 100 nM AG1478 provided complete inhibition of ET-1-induced EGFR-PTK transactivation.
Effects of AG1478 on ET-1-Induced ERK1/2 Stimulation and Contractions of Rabbit BA Rings Without Endothelium
The AG1478 inhibited ET-1-induced ERK1/2 stimulation (Fig. 4) in a concentration-dependent manner, with IC 50 values of approximately 10 nM. Maximal inhibition of approximately 70% was obtained at concentrations of at least 100 nM AG1478.
Similarly, AG1478 inhibited ET-1-induced contractions in a concentration-dependent manner, with IC 50 values of approximately 10 nM (Fig. 5A) . Maximal inhibition of approximately 55% was achieved at concentrations of at least 100 nM (Fig. 5B) .
Effects of AG1478 on ET-1-Induced Vasospasm
We attempted to evaluate in vivo efficacy of EGFR-PTK transactivation on ET-1-induced vasospasm by using AG1478. There was no significant difference among the animal groups for any of the physiological parameters (pH, PCO 2 , PO 2 , or mean arterial pressure) measured at the time of follow-up angiography. The mean diameters of the BAs from each group are shown in Table 1 . The mean diameter of the BAs in animals in Group 1 (730 Ϯ 33 m; six rabbits) was similar to the diameter of the resting BA (735 Ϯ 40 m; 24 rabbits). Moreover, 100 nM AG1478 did not affect the resting BA diameter. All ET-1 injection groups exhibited reduced BA diameters relative to those in the control group. In Group 3 (cisternal injection of 10 nM ET-1), the BA diameters were reduced by 51.8% (352 Ϯ 31 m; six rabbits). Cisternal injections of AG1478 administered 30 minutes before the isternal injection of ET-1 reduced BA contraction and represents a value that is statistically significant. The diameters of AG1478-treated BAs measured 30 minutes after cisternal injection of ET-1 were similar to those measured 2 hours after its injection (data not shown).
Discussion
Analysis of the present study demonstrates that EGFR-PTK transactivation/ERK signaling pathway activated by ET-1 plays important roles in ET-1-induced rabbit BA contraction (Fig. 6) . To confirm the involvement of ERK1/2 in ET-1-induced BA contraction, we used PD98059 for inhibiting ERK1/2 stimulation. The PD98059 inhibits ET-1-induced ERK1/2 stimulation and contraction of BA rings ( Figs. 1 and 2 ). Based on data that the IC 50 values of PD98059 for ET-1-induced contraction in BA rings are similar to those for ET-1-induced ERK1/2 stimulation ( Figs. 1 and 2) , the inhibitory effects of PD98059 on ET-1-induced contraction of BA rings may be due to its inhibitory effects on ERK1/2. These results support the concept of ERK1/2 involvement in ET-1-induced vascular contraction. 5 Moreover, judging from the data that PD98059 inhibits 80% of ET-1-induced contractions in BA rings (Fig. 2B ), ERK1/2 plays a major part in ET-1-induced contraction. The AG1478 inhibits ET-1-induced EGFR-PTK transactivation and ERK1/2 stimulation in BA VSMCs (Figs. 3 and 4) . The ERK1/2 stimulation may be attributable to its inhibitory effects on EGFR-PTK transactivation. Based on the data that ERK1/2 stimulation by ET-1 is partially suppressed by the maximally effective concentration of AG1478 (Fig. 4) , ET-1-induced ERK1/2 stimulation is both dependent on, and independent of, EGFR-PTK transactivation. Furthermore, AG1478 inhibits ET-1-induced contraction in BA rings in a concentration-dependent manner (Fig. 5) . The IC 50 values of AG1478 for ET-1-induced contraction in BA rings ( (Figs. 3 and  4) . Therefore, the inhibitory action of AG1478 on ET-1-induced contraction in BA rings is mediated by a blockade of EGFR-PTK transactivation by ET-1. These results indicate that EGFR-PTK transactivation is involved in ET-1-induced contraction in BA rings. In addition, ERK1/2 is, at the very least, one of the downstream pathways to transactivation-dependent ET-1-induced contraction in BA rings.
Next, we investigated the in vivo role of AG1478 in ET-1-induced BA vasospasm. The AG1478 at 100 nM relaxes ET-1-induced BA vasospasm ( Table 1 ). The mechanism underlying the AG1478-induced relaxation of vasospasm is likely to result, at least partially, from the blockade of EGFR-PTK transactivation for the following reasons: 1) AG1478 is generally accepted as a specific inhibitor of EGFR PTK; 2, 6, 7 and 2) AG1478 of this concentration inhibits ET-1-induced contraction of BA rings (Fig. 5) . These results are in agreement with previous data that the EGFR-PTK transactivation participates in the ET-1-induced contraction of murine aortic ring segments. 2 We recently demonstrated that extracellular Ca ϩϩ influx through voltage-independent Ca ϩϩ channels plays critical roles in ET-1-induced BA contraction 8 and EGFR-PTK transactivation. 7 Therefore, EGFR-PTK transactivation pathway may be one of the major pathways for Ca ϩϩ influx-dependent BA contraction by ET-1 (Fig. 6 ). There is increasing evidence supporting roles for ET-1 in SAH-induced cerebral vasospasm. 4, 13, 14, 18 The results in this study indicate that EGFR-PTK transactivation may play an important role in SAH-induced vasospasm. The effects of AG1478 on SAHinduced vasospasm in rabbit models are now being studied in our laboratory. 
